Therapeutic Targeting of Cancer Stem Cells in Lung, Head and Neck, and Bladder Cancers
Resistance to cancer therapy remains a significant obstacle in treating patients with various solid malignancies. Exposure to current chemotherapeutics and targeted agents invariably leads to therapy resistance, heralding the need for novel agents. Cancer stem cells (CSCs)—a subpopulation of tumor c...
| Main Authors: | , , , , |
|---|---|
| 格式: | 文件 |
| 出版: |
Multidisciplinary Digital Publishing Institute
2021
|
| 在线阅读: | https://hdl.handle.net/1721.1/133177 |
| _version_ | 1826213049475792896 |
|---|---|
| author | Mudra, Sarah E. Sadhukhan, Pritam Ugurlu, M. Talha Alam, Shorna Hoque, Mohammad O. |
| author_facet | Mudra, Sarah E. Sadhukhan, Pritam Ugurlu, M. Talha Alam, Shorna Hoque, Mohammad O. |
| author_sort | Mudra, Sarah E. |
| collection | MIT |
| description | Resistance to cancer therapy remains a significant obstacle in treating patients with various solid malignancies. Exposure to current chemotherapeutics and targeted agents invariably leads to therapy resistance, heralding the need for novel agents. Cancer stem cells (CSCs)—a subpopulation of tumor cells with capacities for self-renewal and multi-lineage differentiation—represent a pool of therapeutically resistant cells. CSCs often share physical and molecular characteristics with the stem cell population of the human body. It remains challenging to selectively target CSCs in therapeutically resistant tumors. The generation of CSCs and induction of therapeutic resistance can be attributed to several deregulated critical growth regulatory signaling pathways such as WNT/β-catenin, Notch, Hippo, and Hedgehog. Beyond growth regulatory pathways, CSCs also change the tumor microenvironment and resist endogenous immune attack. Thus, CSCs can interfere with each stage of carcinogenesis from malignant transformation to the onset of metastasis to tumor recurrence. A thorough review of novel targeted agents to act against CSCs is fundamental for advancing cancer treatment in the setting of both intrinsic and acquired resistance. |
| first_indexed | 2024-09-23T15:42:51Z |
| format | Article |
| id | mit-1721.1/133177 |
| institution | Massachusetts Institute of Technology |
| last_indexed | 2024-09-23T15:42:51Z |
| publishDate | 2021 |
| publisher | Multidisciplinary Digital Publishing Institute |
| record_format | dspace |
| spelling | mit-1721.1/1331772021-11-01T14:36:57Z Therapeutic Targeting of Cancer Stem Cells in Lung, Head and Neck, and Bladder Cancers Mudra, Sarah E. Sadhukhan, Pritam Ugurlu, M. Talha Alam, Shorna Hoque, Mohammad O. Resistance to cancer therapy remains a significant obstacle in treating patients with various solid malignancies. Exposure to current chemotherapeutics and targeted agents invariably leads to therapy resistance, heralding the need for novel agents. Cancer stem cells (CSCs)—a subpopulation of tumor cells with capacities for self-renewal and multi-lineage differentiation—represent a pool of therapeutically resistant cells. CSCs often share physical and molecular characteristics with the stem cell population of the human body. It remains challenging to selectively target CSCs in therapeutically resistant tumors. The generation of CSCs and induction of therapeutic resistance can be attributed to several deregulated critical growth regulatory signaling pathways such as WNT/β-catenin, Notch, Hippo, and Hedgehog. Beyond growth regulatory pathways, CSCs also change the tumor microenvironment and resist endogenous immune attack. Thus, CSCs can interfere with each stage of carcinogenesis from malignant transformation to the onset of metastasis to tumor recurrence. A thorough review of novel targeted agents to act against CSCs is fundamental for advancing cancer treatment in the setting of both intrinsic and acquired resistance. 2021-10-27T17:26:27Z 2021-10-27T17:26:27Z 2021-10-12 2021-10-12T14:18:20Z Article http://purl.org/eprint/type/JournalArticle https://hdl.handle.net/1721.1/133177 Cancers 13 (20): 5098 (2021) PUBLISHER_CC http://dx.doi.org/10.3390/cancers13205098 Creative Commons Attribution https://creativecommons.org/licenses/by/4.0/ application/pdf Multidisciplinary Digital Publishing Institute Multidisciplinary Digital Publishing Institute |
| spellingShingle | Mudra, Sarah E. Sadhukhan, Pritam Ugurlu, M. Talha Alam, Shorna Hoque, Mohammad O. Therapeutic Targeting of Cancer Stem Cells in Lung, Head and Neck, and Bladder Cancers |
| title | Therapeutic Targeting of Cancer Stem Cells in Lung, Head and Neck, and Bladder Cancers |
| title_full | Therapeutic Targeting of Cancer Stem Cells in Lung, Head and Neck, and Bladder Cancers |
| title_fullStr | Therapeutic Targeting of Cancer Stem Cells in Lung, Head and Neck, and Bladder Cancers |
| title_full_unstemmed | Therapeutic Targeting of Cancer Stem Cells in Lung, Head and Neck, and Bladder Cancers |
| title_short | Therapeutic Targeting of Cancer Stem Cells in Lung, Head and Neck, and Bladder Cancers |
| title_sort | therapeutic targeting of cancer stem cells in lung head and neck and bladder cancers |
| url | https://hdl.handle.net/1721.1/133177 |
| work_keys_str_mv | AT mudrasarahe therapeutictargetingofcancerstemcellsinlungheadandneckandbladdercancers AT sadhukhanpritam therapeutictargetingofcancerstemcellsinlungheadandneckandbladdercancers AT ugurlumtalha therapeutictargetingofcancerstemcellsinlungheadandneckandbladdercancers AT alamshorna therapeutictargetingofcancerstemcellsinlungheadandneckandbladdercancers AT hoquemohammado therapeutictargetingofcancerstemcellsinlungheadandneckandbladdercancers |